On Nov. 9, 2020, the NIH reported that a pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form…
On Nov. 9, 2020, a National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine…
On Nov. 9, 2020, a study published in JAMA reported the effect of hydroxychloroquine on clinical status at…
On Nov. 6, 2020, Humanigen announced that it had entered into a Cooperative Research and Development Agreement (CRADA)…
On Nov. 4, 2020, Mateon Therapeutics announced the receipt of approval from Instituto Nacional de Salud (INS), the…
On Nov. 3, 2020, City of Hope announced that it is investigating an innovative treatment for cancer patients…
On Nov. 3, 2020, Medigen Vaccine Biologics (MVC) and the National Institute of Hygiene and Epidemiology (NIHE), a…
On Nov. 2, 2020, CureVac announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the…
On Nov. 2, 2020, Innovation Pharma announced receipt of written feedback from the FDA that is in general…
On Oct. 30, 2020, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced enrollment of volunteers in a phase…
On Oct. 30, 2020, Humanigen announced that MedStar Washington Hospital Center in Washington, D.C. treated its first COVID-19…
On Oct. 30, 2020, Icosavax announced the launch of the companyï¾’s COVID-19 vaccine program with preclinical data on…
On Oct. 28, 2020, Seagen announced the closing of a $1.0 billion equity investment by Merck in 5.0…
On Oct. 28, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Modernaï¾’s…
On Oct. 23, 2020, the U.S. FDA authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford…
On Oct. 23, 2020, AstraZeneca announced that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, had…
On Oct. 22, 2020, Roche and Atea Pharmaceuticals announced they had joined forces in the fight against COVID-19…
On Oct. 22, 2020, a newly developed light-sensing protein called the MCO1 opsin restored vision in blind mice…
On Oct. 21, 2020, results from an international, randomized, controlled clinical trial indicated that a four-month daily treatment…
On Oct. 21, 2020, ImmunityBio and NantKwest announced that the first patient had been dosed in the Phase…
On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina Poder Ejecutivo Nacional, the…
On Oct. 19, 2020, LabCorp announced a test that provided a quantitative measurement of an individualï¾’s SARS-CoV-2 IgG…
On Oct. 16, 2020, the NIH launched an adaptive Phase 3 clinical trial to evaluate the safety and…
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
On Oct. 14, 2020, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
On Oct. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyï¾’s Investigational New…
On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan…
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to…
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…